MINOCA: When the Heart Attack Has Normal Arteries

MINOCA, myocardial infarction with non-obstructive coronary arteries, represents 8% of all heart attacks and affects women in 61% of cases. Despite coronary angiography showing less than 50% stenosis, these patients sustain real myocardial injury with elevated troponin and face one-year mortality rates of 2 to 5%, equivalent to obstructive MI. Cardiac MRI identifies the underlying etiology in 70 to 80% of cases, yet most MINOCA patients are discharged without further workup or treatment. The 2019 AHA Scientific Statement established MINOCA as a working diagnosis requiring systematic investigation, not a final answer meaning the patient is fine.

Her troponin was elevated. Her angiogram was clean. She was told to go home. Her cardiologist at the academic center reviewed the case eight months later: MINOCA. She had had a real heart attack. Nobody told her.

This scenario plays out in catheterization labs every day. A woman presents with chest pain, nausea, and elevated cardiac enzymes. The interventional cardiologist threads a catheter through her radial artery, injects contrast, and sees no significant blockages. The arteries look pristine on fluoroscopy. The cardiologist walks to the waiting room and delivers what sounds like good news.

“Your arteries are clean. There’s nothing to stent. You can go home.”

She leaves the hospital with no diagnosis, no treatment plan, and no follow-up. She assumes she imagined the whole thing. Her primary care physician receives a discharge summary stating “non-cardiac chest pain, negative catheterization.” The troponin elevation gets filed away as a lab anomaly.

Eight months later, she develops heart failure. The echo shows a regional wall motion abnormality. The scar pattern on cardiac MRI confirms an old infarct. She had a heart attack in that emergency room. The clean angiogram did not mean she was fine. It meant we stopped looking too soon.

The Diagnostic Definition That Gets Ignored

MINOCA requires three criteria, all of which must be present. First, elevated cardiac troponin with the characteristic rise and fall pattern that distinguishes true myocardial injury from chronic elevation. Second, clinical evidence of myocardial ischemia through symptoms, new ECG changes, or imaging evidence of new loss of viable myocardium. Third, coronary angiography demonstrating no stenosis of 50% or greater in any major epicardial vessel. Tamis-Holland 2019

The 2019 American Heart Association Scientific Statement codified this definition and made a critical distinction: MINOCA is a working diagnosis, not a final answer. The clean angiogram does not explain why the troponin rose. It does not explain why the ECG changed. It simply means the mechanism was not a ruptured plaque creating a flow-limiting obstruction.

The prevalence is not trivial. A pooled analysis of 23 studies encompassing 806,851 acute MI patients found MINOCA in 8.1% of presentations, with ranges spanning 3 to 15% depending on the population studied. 5 / Solid In absolute numbers, this translates to approximately 80,000 MINOCA cases annually in the United States alone.

The sex distribution tells the real story. In the VIRGO study examining 2,690 young women with MI, 10.5% had MINOCA compared to 3.4% of age-matched men. Overall, 61% of all MINOCA patients are female. Safdar 2018 This is not a rare variant of heart disease. This is how heart disease commonly presents in women.

Six Mechanisms Hiding Behind the Clean Angiogram

MINOCA is an umbrella term covering at least six distinct pathophysiological mechanisms. Each requires different treatment. Sending the patient home without determining which mechanism caused her heart attack is like diagnosing “abdominal pain” and declining to check whether it was appendicitis or gastritis.

Plaque erosion differs fundamentally from plaque rupture. In rupture, a lipid-rich plaque cap tears, exposing thrombogenic contents to flowing blood. In erosion, the endothelium denudes over a stable plaque, creating a thrombus that may embolize or resolve before the angiogram. The MINOCA-TR study using optical coherence tomography identified plaque erosion in 31% of cases. Niccoli 2020 This mechanism predominates in premenopausal women.

Coronary vasospasm involves transient arterial constriction severe enough to cause ischemia. The spasm may resolve before angiography, leaving arteries that appear structurally normal. Provocative testing with acetylcholine or ergonovine can unmask this mechanism. Montone 2018 demonstrated that invasive provocative testing in MINOCA patients is both safe and diagnostically valuable.

Spontaneous coronary artery dissection creates a false lumen within the arterial wall that may compress the true lumen. The dissection may heal spontaneously, or the flap may be subtle enough to miss on standard angiography. SCAD accounts for up to 4% of all MI and up to 35% of MI in women under 50.

Takotsubo cardiomyopathy causes apical ballooning of the left ventricle, typically following severe emotional or physical stress. The coronary arteries remain patent, but catecholamine toxicity causes myocardial stunning. Troponin elevates. The pattern on cardiac MRI is diagnostic.

Coronary microvascular dysfunction occurs when the small vessels that angiography cannot visualize become impaired. The epicardial arteries appear normal because they are normal. The disease lives in the microcirculation. Taqueti 2017 demonstrated that microvascular dysfunction explains the excess cardiovascular risk in women referred for angiography.

Myocarditis mimics MI through viral or autoimmune inflammation of the myocardium. Troponin rises. ECG changes appear. The patient has chest pain. Cardiac MRI distinguishes myocarditis from infarction through characteristic patterns of late gadolinium enhancement.

Women don’t die from what they have. Women die from what they hold. They hold the dismissal of their symptoms. They hold the discharge paperwork that says nothing was wrong. They hold the uncertainty that makes them doubt their own bodies.

The Cardiac MRI Imperative

Cardiac MRI identifies the underlying MINOCA etiology in 70 to 80% of cases. This is not optional advanced imaging. This is the diagnostic standard for a condition that otherwise leaves patients untreated. 5 / Solid

A prospective study of 170 consecutive MINOCA patients demonstrated the yield: cardiac MRI diagnosed myocarditis in 25%, Takotsubo cardiomyopathy in 18%, and myocardial infarction in 22%. Dastidar 2017 The remaining cases showed either dual pathology, cardiomyopathy, or normal findings that directed further workup.

The timing matters. Acute edema and inflammation patterns fade within weeks. Early enhancement patterns that distinguish myocarditis from infarction become less clear as tissue remodels. Current guidance recommends cardiac MRI within two weeks of presentation, ideally within the index hospitalization.

The practical reality falls short. A national survey found that fewer than 25% of MINOCA patients receive cardiac MRI during their initial hospitalization. Many never receive it at all. The reasons are logistical, not medical. MRI scanners have limited availability. The referral requires additional steps. The patient has already been told her arteries are fine.

The consequences are measurable. MINOCA patients diagnosed with a specific etiology receive targeted treatment. Vasospasm patients get calcium channel blockers. SCAD patients get conservative management without aggressive antiplatelet therapy. Takotsubo patients get beta-blockers and surveillance. Myocarditis patients avoid strenuous activity during the healing phase.

MINOCA patients without etiologic diagnosis receive nothing. They are told to follow up with their primary care physician. They are told their heart attack was not a real heart attack. They are told to reduce stress, as if stress reduction prevents plaque erosion or coronary spasm.

Mortality That Matches Obstructive MI

The clean angiogram creates a dangerous illusion of safety. Patients and physicians assume that normal-appearing arteries mean normal outcomes. The data say otherwise.

One-year mortality for MINOCA ranges from 2 to 5%, directly comparable to the 3 to 6% mortality for obstructive MI. Lindahl 2017 5 / Solid The Swedish SWEDEHEART registry followed 9,092 MINOCA patients and found an adjusted hazard ratio for death at one year that did not significantly differ from obstructive MI after accounting for age and comorbidities.

Long-term outcomes are equally concerning. Over four years of follow-up, 23.9% of MINOCA patients experienced major adverse cardiovascular events including death, MI recurrence, heart failure hospitalization, and stroke. These patients were not fine. Their arteries simply did not show the blockages we expected to find.

The Perimenopause Vascular Inflection Window explains why women predominate in MINOCA statistics. Between ages 45 and 55, declining estrogen removes its protective effects on endothelial function and vascular reactivity. Coronary vasospasm becomes more common. Microvascular dysfunction accelerates. The small vessels that do not appear on angiography become the primary site of disease.

This is the period when cardiovascular risk increases most sharply in women. Yet standard risk calculators systematically underestimate female risk. Framingham-derived scores weight traditional risk factors that predict obstructive disease in men. They miss the microvascular dysfunction, vasospasm, and plaque erosion patterns that cause MINOCA in women.

The mechanism matters for prognosis. MINOCA patients with true myocardial infarction on MRI have worse outcomes than those with Takotsubo or myocarditis. Treatment that matches the mechanism improves survival. Treatment chosen randomly, or no treatment at all, does not.

Treatment That Follows Diagnosis

Secondary prevention reduces MINOCA mortality, but only when implemented. The Swedish registry demonstrated that statins plus ACE inhibitors or angiotensin receptor blockers reduced the hazard of major adverse cardiovascular events by 23% compared to no secondary prevention. 4 / Promising

The challenge is that treatment differs by mechanism.

For plaque erosion without significant residual stenosis, standard secondary prevention applies: statin therapy to LDL below 70 mg/dL, aspirin, and consideration of additional antiplatelet therapy based on thrombus burden seen on intravascular imaging.

For coronary vasospasm, calcium channel blockers are first-line. Nitrates provide additional benefit. Beta-blockers, which typically protect against coronary events, may paradoxically worsen vasospasm by leaving alpha-mediated constriction unopposed.

For SCAD, aggressive antiplatelet and anticoagulant therapy may extend the dissection plane. Initial conservative management allows healing. Long-term prevention focuses on blood pressure control and avoiding precipitants.

For Takotsubo cardiomyopathy, beta-blockers reduce recurrence, though evidence remains limited. ACE inhibitors support ventricular remodeling. Most importantly, recognition allows appropriate monitoring and avoidance of catecholamine surges.

For microvascular dysfunction, Bairey Merz 2020 outlined the treatment paradigm: lifestyle modification, risk factor control, and consideration of agents like ranolazine or low-dose tricyclic antidepressants for refractory symptoms.

For myocarditis, no specific treatment accelerates healing, but activity restriction prevents arrhythmias during the inflammatory phase. Immunosuppression may help in autoimmune cases.

None of this treatment can happen without diagnosis. Diagnosis requires cardiac MRI. Cardiac MRI requires a physician who refuses to accept “clean angiogram” as the final answer.

The Advocacy Checklist

If you present with chest pain and elevated troponin, and your angiogram shows no significant blockages, you have not received good news. You have received an incomplete evaluation.

Ask for the diagnosis. “My troponin was elevated. My ECG showed changes. What caused my heart attack?” If the answer is “We don’t know, but your arteries look fine,” that is not acceptable.

Ask for cardiac MRI. “I understand cardiac MRI can identify the cause in 70 to 80% of MINOCA cases. When is mine scheduled?” If the answer is that MRI is not necessary because your arteries are clean, that answer conflicts with the 2019 AHA Scientific Statement on MINOCA.

Ask about provocative testing. “Has coronary vasospasm been excluded? Would acetylcholine or ergonovine testing be appropriate?” Not every patient needs provocative testing, but the question should be asked.

Ask about secondary prevention. “What medications should I take to reduce my risk of recurrence? What is my target LDL? Should I be on an ACE inhibitor or ARB?” MINOCA is not a benign condition. It requires treatment.

Ask about follow-up. “When will I see a cardiologist again? What symptoms should bring me back to the emergency room?” MINOCA patients deserve the same close follow-up as obstructive MI patients.

Document the conversation. If recommendations are declined or if testing is refused, ask for the reasoning to be documented in your medical record. Documentation changes behavior.

At your next appointment, bring this article. Ask these questions by name: “What was my MINOCA mechanism? When am I getting cardiac MRI? What is my secondary prevention regimen?” Print the questions. Write down the answers. Follow up in writing if the answers are unsatisfactory.

Frequently Asked Questions

Can you have a heart attack with clean arteries?

Yes. MINOCA is defined by elevated cardiac troponin with rise and fall pattern, clinical evidence of myocardial ischemia through symptoms or ECG changes, and coronary angiography showing no stenosis of 50% or greater in any major epicardial vessel. The angiogram appears clean because the mechanism was not a flow-limiting plaque rupture. Plaque erosion, coronary vasospasm, spontaneous coronary artery dissection, Takotsubo cardiomyopathy, microvascular dysfunction, and myocarditis can all cause troponin elevation and myocardial injury without visible obstruction. The heart attack is real. The damage is real. The clean angiogram means we need to look deeper, not that nothing happened.

Why is MINOCA more common in women?

Women have higher rates of every non-obstructive ischemic mechanism. Coronary vasospasm occurs more frequently in women, particularly after menopause when estrogen no longer buffers vascular reactivity. Spontaneous coronary artery dissection accounts for up to 35% of MI in women under 50 and is rare in men. Takotsubo cardiomyopathy affects women in approximately 90% of cases. Microvascular dysfunction, which causes ischemia in vessels too small to see on angiography, predominates in women. Plaque erosion rather than plaque rupture is more common in premenopausal women. These mechanisms cause real heart attacks without the classic pattern that angiography was designed to detect.

What test diagnoses the cause of MINOCA?

Cardiac MRI is the essential diagnostic test. It identifies the underlying cause in 70 to 80% of MINOCA cases by distinguishing myocarditis from true infarction, detecting Takotsubo cardiomyopathy patterns, and identifying the location and extent of myocardial injury. The 2019 AHA Scientific Statement recommends cardiac MRI for all MINOCA patients, ideally within two weeks of presentation while acute findings are still visible. Optical coherence tomography during catheterization can identify plaque erosion or subtle dissection flaps. Provocative testing with acetylcholine can unmask coronary vasospasm. But cardiac MRI is the first-line test that should not be skipped.

Is MINOCA dangerous if the arteries look normal?

MINOCA carries one-year mortality rates of 2 to 5%, equivalent to obstructive MI mortality of 3 to 6%. The Swedish SWEDEHEART registry following 9,092 MINOCA patients found 23.9% experienced major adverse cardiovascular events over four years including death, recurrent MI, heart failure, and stroke. The clean angiogram creates an illusion of safety that the outcome data do not support. Patients diagnosed with MINOCA require secondary prevention treatment, regular cardiology follow-up, and recognition that they have survived a cardiovascular event with ongoing risk.

What medications treat MINOCA?

Treatment depends entirely on the underlying mechanism, which is why diagnostic workup matters. For plaque erosion, standard secondary prevention applies: statins, aspirin, ACE inhibitors or ARBs. For coronary vasospasm, calcium channel blockers are first-line with nitrates for additional benefit. For SCAD, initial conservative management without aggressive antiplatelet therapy allows healing. For Takotsubo, beta-blockers reduce recurrence and ACE inhibitors support ventricular remodeling. For microvascular dysfunction, risk factor control and consideration of ranolazine. For myocarditis, activity restriction during the inflammatory phase. Swedish registry data showed statins plus ACE inhibitors or ARBs reduced major adverse cardiovascular events by 23% in MINOCA patients compared to no secondary prevention.